Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Promedior, founded in 2006 and headquartered in Lexington, Massachusetts, is a clinical-stage immunotherapy company focused on developing targeted therapeutics for fibrosis-related diseases. The company's innovative approach aims to treat conditions where excessive scar tissue compromises organ function, including rare diseases and more common ailments like age-related macular degeneration and nonalcoholic steatohepatitis (NASH).
Since its inception, Promedior has made significant strides in the field of fibrosis treatment, raising a total of $64.4 million in funding. The company's pioneering work in this area has attracted attention from major players in the pharmaceutical industry. In a notable development, Promedior was acquired by Roche on November 15, 2019, in a deal valued between $390 million and $1.39 billion.
Given Promedior's acquisition by Roche, the company is no longer pursuing an initial public offering (IPO). As a subsidiary of a larger pharmaceutical corporation, Promedior's focus has likely shifted to advancing its research and development efforts under the umbrella of its parent company. For investors interested in gaining exposure to Promedior's potential, they may consider exploring opportunities within Roche's publicly traded stock.
While Promedior itself is not available for direct investment on the public markets, its acquisition by Roche underscores the value and potential of its fibrosis-focused therapeutics. This strategic move by Roche highlights the growing importance of innovative treatments in the field of immunotherapy and fibrosis-related diseases.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Promedior's IPO prospects remain uncertain, investors interested in the biotechnology sector don't have to wait on the sidelines. At Linqto, we offer members access to interests in promising pre-IPO companies, including potential leaders in the biotech industry like Promedior. Our platform allows accredited investors to diversify their portfolios with lower minimum investments, potentially benefiting from the growth of innovative companies before they go public.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
